This is a multisite (approximately 3 sites), open-label, non-randomized, single-dose study in subjects with severely impaired kidney function and healthy subjects. About 12 subjects will be assigned to two groups: Group 1: 6 with severely impaired kidney function , and Group 2: 6 subjects with normal kidney function.